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Abstract
Objective-To quantify patterns and trends in
incidence of AIDS associated with transfusion of
blood and its products in 14 European countries and
the United States.
Design-Data were derived from the World
Health Organisation's European non-aggregate
AIDS dataset and, for the United States, from the
Centers for Disease Control AIDS public infor-
mation dataset. Rates were standardised by using
the world standard populations and adjusted for
reporting delays in each country.
Subjects-Cases ofAIDS in patients with haemo-
philia and recipients oftransfusions.
Results-Overall, between 1985 and 1993 almost
6000 cases of AIDS associated with transfusions
were registered in the 14 European countries con-
sidered and over 8000 in the United States between
1985 and 1992. Most European countries had annual
age adjusted rates lower than 0 5 per million children
aged 12 or less and between 1 and 2 per million
adults. The United States had rates around 1 per
million children and S per million adults in the most
recent period. For children, the highest rates were
generally reached in 1985-7, whereas in adults the
highest rates were in the late 1980s. France had the
highest overall incidence of AIDS related to trans-
fusion in Europe (3.3 per million). Romania had a
major epidemic in children (over 30 cases per million
children in 1988-90). Incidence rates of AIDS as-
sociated with transfusion were still increasing in
some southern European countries in the early
1990s.
Conclusions-Apart from in France and Romania
it is clear that rates ofbloodborne AIDS in European
countries are lower than those registered in the
United States.
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Introduction
The issue of AIDS transmission through blood and
its products has been recognised since the early 1980s,
before the identification of the causative agent, HIV.'
Between 1983 and 1985 major steps were taken to
control a bloodborne HIV epidemic,2 but the schedules
and the degree of adoption of these measures have
been different in various European countries as com-
pared with in the United States.-'0
Although several problems-for example, under-
reporting, inaccuracies in HIV transmission categor-
ies, lack of information on the timing of and reason for
transfusion, etc-hamper the comparison of incidence
of AIDS in different areas, this report represents an
attempt to assess systematically cases of AIDS in
haemophilic patients and transfusion recipients in dif-
ferent European countries and, for a comparison,
in the United States in terms of age standardised
incidence rates.
Materials and methods
For European countries, official AIDS notification
data for the period 1985-93 were derived from the
European non-aggregate AIDS dataset (ENAADS) up
to March 1994. Data on the United States were derived
from the AIDS public information dataset (PIDS) up
to June 1993."-'5 Countries which in the examined
period reported fewer than 50 bloodbome AIDS cases
or did not send disaggregated data to ENAADS were
not included. Rates were standardised for age 1016 and
corrected for reporting delay7 '7 in each country.
Results
Table 1 gives the number of cases of AIDS associ-
ated with blood and its products in various countries
overall and by sex, age group, and transmission
category (transfusion recipients and patients with
haemophilia). Data are adjusted for delays in report-
ing. The figure shows the number of cases and age
adjusted rates of bloodbome AIDS over the period
1985-93 in the 14 European countries considered
and the United States, together with proportions of
haemophilic patients and transfusion recipients. The
burden of HIV infection was especially heavy in
transfusion recipients in France and in Romania,
where they accounted for 74% and 98%, respectively,
of cases associated with blood or its products.
Table 2 shows annual incidence rates in children
aged 0-12 years and adults and by HIV transmission
category for three subsequent calendar periods. In
children the highest rates were generally observed in
1985-7 or 1988-90 and declined thereafter. In 1991-3
three European countries, besides Romania, showed
incidences above 0 5 per million children: France,
Portugal, and Belgium. In adults, France showed
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Table 1-Distribution of AIDS cases associated with blood and blood products by country, sex, age, transmission
category, andpercentages oftotalAIDS cases, 1985-93
Transmission category Proportion
Sex Age (years) of total
Haemophilic Transfusion AIDS cases
Country Male Female 0-12 13-49 > 50 patients recipients (YO)
Austria 69 17 5 65 16 60 26 7.5
Belgium 49 45 11 57 26 9 85 6.0
Denmark 43 12 0 37 18 34 21 4.0
France 1213 713 95 949 881 417 1509 5.9
Germany 552 136 23 471 193 431 257 5-7
Greece 90 19 9 79 21 67 42 12.2
Italy 393 108 25 357 119 230 271 2.3
Netherlands 77 20 11 55 31 55 42 3.2
Portugal 99 33 11 89 32 50 82 6.1
Romania 374 280 630 20 4 13 641 23.9
Spain 655 142 65 557 175 529 268 2-8
Sweden 59 12 2 26 43 32 39 7.2
Switzerland 54 24 2 44 32 25 53 1.9
United Kingdom 466 76 26 411 105 439 103 5.7
United States* 5777 2246 493 4308 3223 2401 5623 2-8
* 1985-92.
Table 2-Annual incidences ofAIDS cases associated with blood and bloodproducts permillion (age standardised, world)
by country, age group, transmission category, and time
Children 10-12 years) Adults Haemophilic patients Transfusion recipients
Country 1985-7 1988-90 1991-3 1985-7 1988-90 1991-3 1985-7 1988-90 1991-3 1985-7 1988-90 1991-3
Austria 0.53 0-76 0.00 0.94 1.71 1.98 0.62 0.95 1.18 0.21 0.50 0.26
Belgium 0.25 1.28 0.50 0.82 1.17 1.38 0.00 0.23 0.15 0.66 0.98 0.99
Denmark 0-00 0-00 0.00 1.17 1-27 1.89 0.67 0.52 0.98 0-18 0-40 0.39
France 1.11 0.90 0-74 2.29 5.10 5.05 0.39 1.00 1.15 1.58 2.95 2.72
Germany 0-34 0-14 0-13 0-79 1.34 1.39 0.47 0.74 0.63 0.20 0.27 0.41
Greece 0.27 0.53 0-45 0.89 1.81 1.97 0.51 0.78 1.04 0.21 0.68 0-51
Italy 0.27 0.32 0.18 0.53 1-29 1-74 0.27 0.53 0 61 0.19 0.49 0-70
Netherlands 0.40 0.32 0.37 0.29 0.96 1.03 0.11 0.46 0.57 0-20 0.33 0.28
Portugal 0-57 0.37 0-53 0.61 2.23 2-50 0.46 0.67 0-59 0.15 1.05 1.37
Romania 0.00 33-89 16-11 0.08 0.12 0.27 0.03 0.12 0.09 0.03 9.25 4.52
Spain 0.88 1.01 0.31 1.32 3.34 3.56 0.94 1.95 1.69 0.26 0.75 0.98
Sweden 0.18 019 0.00 0.99 1.29 0.65 0-34 0.47 0.38 0.43 0.52 0.09
Switzerland 0.00 0.25 0.28 0.45 2.14 1.88 0.15 0.67 0.56 0.18 0.95 0.89
United Kingdom 0-29 0.21 0.27 0.80 1-68 1.44 0.51 1-10 0-88 0-15 0-18 0.24
United States* 1.08 1.15 0.74 3.51 5.38 5.02 0.84 1.41 1.44 2.01 2.82 2.40
*1985-92.
the highest incidence rates over the examined
period, similar to those seen for the United States.
Adult incidence rates peaked in 1988-90 in Sweden,
Switzerland, and the United Kingdom, as well as in
France and the United States. Conversely, no clear
decline was seen in other European countries, and
upward trends persisted up to 1991-3 in Denmark,
Italy, Portugal, and Spain. The separate inspection
of data on haemophilic patients and transfusion recip-
ients revealed generally consistent patterns. Recent
declines in the numbers of AIDS cases associated with
transfusions were seen in France and the United
States, whereas an upward trend persisted in several
southern European countries.
Discussion
AIDS linked to blood and blood derivatives has been
a major problem in Europe, at least up to the mid-
1980s. Two European countries emerged with sub-
stantial excesses of AIDS cases. One was Romania,
where the spread of AIDS among children was due to
misuse of blood, blood products, and reusable non-
sterilised needles (that is, nosocomial infection). The
other was France, partly on account of the delay by
French government officials in approving an American
made blood test for HIV infection.34
It is clear that transfusion recipients and haemo-
philics were differently represented in various
countries on account of different degrees of safety
achieved in blood supplies (generally from local
donors) and supplies of factor VIII (mostly imported).
The former accounted for more than 60% of cases of
bloodborne AIDS in Belgium, Portugal, Switzerland,
and France. Haemophilic patients predominated over
transfusion recipients (> 60%) in Denmark, Germany,
Spain, and, most notably, in the United Kingdom.
The declines or at least the levelling off of rates of
AIDS cases diagnosed in haemophilic patients and
transfusion recipients in most European countries
since the early 1 990s, also in the lack of information on
year of transfusion, is evidence of the favourable
impact of control procedures and treatment of blood
and its products from 1984 onwards.2 As in the United
States89 improvements were seen earlier in children
largely because they have the shortest incubation
period between infection and AIDS diagnosis'821 and
partly on account of the constraints of the incubation
period imposed on this group by the definition of the
age limit of 12 years. Some less encouraging patterns
are, however, present among adults, with persisting
upward trends in Denmark, Italy, and Spain.
Apart from France and Romania it is, however, clear
that rates of bloodborne AIDS in other examined
European countries are lower than those registered in
the United States.
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Key messages
* Major differences exist among European countries in the timing and
degree of adoption ofmeasures to control a bloodborne HIV epidemic
* Despite many weaknesses, official AIDS notification data help in under-
standing the size of the problem in Europe and the United States
* Annual age adjusted incidence rates of bloodborne AIDS for 1985-93 were
over 3 per million in Romania, the United States, and France
* Rates were lower than 1 per million in Italy, Germany, Sweden, and the
Netherlands
* Declines in incidence ofbloodbome AIDS in Europe and the United States
started in the late 1980s (children) and early 1990s (adults)
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Abstract
Objectives-To design user friendly guides to
prognosis for patients who have had invasive
primary cutaneous malignant melanomas surgically
excised.
Design-Adaptation of the classification tree
method was used to derive prognostic trees for four
different subgroups ofmalignant melanoma patients
in whom known and possible prognostic variables
interacted in different ways.
Setting-Scotland.
Subjects-Statistical modelling for prognostic
trees was based on 1978 patients whose primary
malignant melanoma was first diagnosed in 1979-86
for whom five year follow up and all relevant clinical
pathological data were available. The resultant
model was validated with 300 patients first diagnosed
in 1987 for whom the same information was avail-
able.
Main outcome measures-Actual and predicted
rate ofsurvival after diagnosis ofprimary cutaneous
malignant melanoma.
Results-The four subgroups of patients were
men and women with ulcerated and non-ulcerated
cutaneous primary melanomas. Validation of the
model showed excellent agreement between actual
status ofpatients in the relevant subgroups and their
status as predicted by the model.
Conclusions-The prognostic trees are simple to
use and give more accurate prognosis for individual
patients than is currently available from tumour
thickness alone.
Introduction
Studies have shown that several factors affect the
prognosis and survival of patients with primary
invasive cutaneous malignant melanoma.'4 Most
reports agree that tumour thickness is the most
important prognostic factor, but several other factors
seem to interact, including sex, presence or absence of
ulceration, level of invasion, age at diagnosis, site of
tumour, and type oftumour.
We previously reported the results of proportional
hazards models developed by the Scottish Melanoma
Group to predict survival of patients with primary
cutaneous malignant melanoma.5 Four distinct sub-
groups of patients were identified from this analysis-
men and women with ulcerated or non-ulcerated
lesions. Within each of these subgroups different sets
of prognostic factors were identified, although tumour
thickness was always a key factor. For example, among
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